Navigation Links
Boston Scientific Acquires Labcoat Limited
Date:1/6/2009

to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACTS:              Paul Donovan
                           508-650-8541 (office)
               
'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Approves Boston Scientifics Express(R) SD Renal Stent System
2. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
3. Boston Scientific to Participate in Piper Jaffray Health Care Conference
4. Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory
5. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
6. FDA Approves Boston Scientifics Apex(TM) PTCA Dilatation Catheter
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability
9. Boston Scientific Announces Results for Third Quarter Ended September 30, 2008
10. Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet
11. Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... BARBARA, CALIFORNIA (PRWEB) March 04, 2015 ... consulting firm in the life sciences industry, hired ... Blewitt leads the Cloud Compliance Services and Solutions ... companies utilize cloud based applications while maintaining compliance with ... years, Blewitt has been an accomplished life sciences regulatory ...
(Date:3/4/2015)... San Bruno, CA. (PRWEB) March 04, 2015 ... Organization (CRO) headquartered in the San Francisco Bay Area, ... Clinical Trials (OCT) Israel Conference 2015 on March ... PRC Clinical seeks to build relationships with Israeli life ... Administration (FDA) clinical trials. The company’s services span all ...
(Date:3/4/2015)... Korea , March 4, 2015 Vegalab ... company, in August of last year. As part of ... Kyung Bon Koo continuing his role as CEO ... President of Vegalab S.A., will work alongside Koo and ... Photo - http://photos.prnewswire.com/prnh/20150303/179218 Koo ...
(Date:3/4/2015)...   ... Therapie, Strahlendosismanagement und IT-Lösungen für die gesamte Kette ... (NYSE: PHG, AEX: PHIA) gab heute seine ... bekannt, der vom 4. bis 8. März in ... Nr. 102 and 110 wird das Unternehmen ...
Breaking Biology Technology:USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6
... ... 16 Reportlinker.com announces that a new ... , The Future of Nutrigenomics: New ... , http://www.reportlinker.com/p0177850/The-Future-of-Nutrigenomics-New-opportunities-in-personalized-nutrition-and-food-pharma-collaboration.html , Nutrigenomics explores ...
... , -- Company to Host Clinical Update Conference Call ... Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) today announced that ... Medicines and Healthcare products Regulatory Agency (MHRA) to conduct its ... carboplatin in patients with platinum-refractory head and neck cancers. This ...
... , , , , ROCKVILLE, Md. ... VNDA ), a biopharmaceutical company focused on the development and ... financial and operational results for the fourth quarter and full year ... net loss of $9.2 million for the fourth quarter ...
Cached Biology Technology:Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 2Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 3Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 4Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 5Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 6Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 5Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 2Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 3Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 4Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 5Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 6Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 7Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 8Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 9Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 10Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 11Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 12Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 13Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 14Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 15Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 16Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 17Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 18
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
(Date:2/5/2015)... , Jan. 27, 2015   ... of globally deployed, innovative test solutions for ... the delivery of its TS-323 GENASYS ... Systems Company (LMSSC). GENASYS is a high-performance ... of mission-critical applications that require performance functional ...
(Date:2/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ... "Global Biometrics Market (2014-2020): Market Forecast By Technologies, ... to their offering. , In ... is anticipated to overtake North America ... spending towards IT security, government biometric based projects ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... people may joke about living on caffeine, but scientists ... to do that literally. Their report in the ... "addicted" to caffeine in a way that promises practical ... medications for asthma. Jeffrey E. Barrick and colleagues ...
... March 26, 2013 Like it or not and despite ... du jour for movie-making in Hollywood. It now turns out ... According to a new study published in Biological ... distinct systems: one system that directs attention to affective states ...
... treating Lyme disease. However, nearly one quarter of ... available serological tests have poor sensitivity and specificity ... may go untreated and thus progress to late-stage ... invasive treatments, as well as persistent symptoms. ...
Cached Biology News:Human emotion: We report our feelings in 3-D 2Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device 2Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device 3Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device 4
... which pioneered the blending of thermostable DNA ... Expand Long Template PCR Systems, now introduces ... the first product of a family of ... combines Taq DNA Polymerase with a novel ...
... 13 5'G AATTC3' 3'CTTAA G5' Inactivation Conditions: Heat ... precipitation. Storage Conditions: 10mM Tris-HCl (pH 7.5), 100mM ... 0.01% BSA, 50% glycerol. Shipping and Storage: Shipped ... One unit is defined as the amount of ...
... 3'CGGN NNNNCCG5' Inactivation Conditions: Heat inactivation at ... followed by ethanol precipitation. Storage Conditions: 10mM ... 1.0mM DTT, 0.01% BSA, 50% glycerol. Shipping ... at -20C. Unit Definition: One unit is ...
...
Biology Products: